• when accuracy means everything

    when accuracy means everything
  • complete panel of diagnostics

    complete panel of diagnostics
  • at the end of every test is a patient

    at the end of every test is a patient
  • early detection improves outcomes

    early detection improves outcomes
  • your laboratory next door

    your laboratory next door

The total solution in autoimmunity™

Immco Diagnostics develops and distributes autoimmune disease diagnostics and reagents to labs worldwide. We offer laboratory testing of autoimmune diseases for the US healthcare market. Our contract research organization supports clinical research trials for pharmaceutical and biotech clients. Immco assay development led to the first immunofluorescence assay for diagnosing celiac disease and the first Western blot assay for autoimmune hearing loss. Our new line of enhanced ELISA assays provides standardized calibration systems, an industry first. We are continually expanding our product offering. So come visit us often as we focus on our principal mission at Immco—providing the total solution in autoimmunity™.

Products

Products

Immco offers a wide selection of autoimmune diagnostics under our leading brands: ImmuGlo,ImmuLisa, and ImmuBlot

Immunofluorescence microscopy is the cornerstone of autoimmune diagnostics at Immco. As a leader in developing IFA (indirect immunofluoresence assays), we offer a full range of IFA products for detecting autoimmune disease. ImmuGlo is supported with flexible configurations and high quality reagents that ensure reproducibility and ease of use.

Immco ELISAs (enzyme linked immunosorbent assays) feature highly accurate qualitative and quantitative antibody detection for proper diagnosis of autoimmune disorders. Introduction of our new ImmuLisa Enhanced assays features industry leading advantages:

  • Antigens are selected and presented in a highly purified form for the highest accuracy
  • Standardized component sets and methods provide greater reproducibility
  • Optimal detection systems yield enhanced sensitivity and specificity
  • Optimal design for performance on all major automated ELISA platforms
  • Choice of single or multiple point calibration for greater flexibility
  • Longer shelf life up to 18 months to support laboratory needs.

Immco's ImmuBlot™ uses Western blot assay methodology to provide highly sensitive, qualitative detection of autoantibodies in serum. ImmuBlot assays feature leading reliability and are primarily used to identify specific analytes or serve as confirmatory tests.

Lab Services

Lab Services

Immco Reference Lab Services, specializing in autoimmune diseases and immunopathology, provides laboratory testing with over 200 cutting edge diagnostics using direct and indirect immunofluorescence (IFA), enzyme linked immunosorbent assays (ELISA), Western blot detection methods and biopsy studies to support healthcare practitioners across a wide clinical spectrum. We provide histopathology and serology for oral diagnostics, autoimmunology and immunogenetics for common autoimmune diseases such as lupus, rheumatoid arthritis, celiac disease, polymyositis, systemic sclerosis, and thyroiditis, as well as the less prevalent autoimmune disorders. Our laboratory testing includes:

  • Connective tissue disorder diagnostics for systemic lupus erythematosus, scleroderma, rheumatoid arthritis, and vasculitis
  • Gastrointestinal disease diagnostics including celiac disease, inflammatory bowel disorders, pernicious anemia and autoimmune gastritis
  • Liver disease diagnostics such as autoimmune hepatitis and primary biliary cirrhosis
  • Vesiculo-bullous disorder diagnostics for pemphigus, pemphigoid, and epidermolysis bullosa acquisita
  • Endocrine disorder diagnostics including Type 1 diabetes, Graves' disease, Hashimoto's thyroiditis, Addison's disease and premature ovarian dysfunction
  • Neurological diagnostics for peripheral neuropathies, paraneoplastic syndromes, Guillain-Barré Syndrome, Miller Fisher Syndrome, neuropsychiatric lupus, and myasthenia gravis
  • Cardiovascular diagnostics for patients at risk for atherosclerosis, myocarditis, and cardiomyopathy.

Featured Product

Clinical Specialties

Immco is Proud to Announce FDA Approval of ImmuLisa Enhanced™ Celiac Fusion,  a tTG/DGP ELISA detecting both human tissue transglutaminase (tTG) and deamidated gliadin peptide (DGP) antibodies of IgA and IgG isotypes and provides an ideal first line test for diagnosing celiac disease.




For more information on 5157 Celiac Fusion ELISA and all of Immco’s ELISA’s products, click on: http://www.immco.com/products/immulisa-elisa.aspx 

.